These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6678874)

  • 1. The treatment of acute leukemia with continuous infusion L-Alanosine.
    Weick JK; Tranum BL; Morrison FS
    Invest New Drugs; 1983; 1(3):249-51. PubMed ID: 6678874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of L-alanosine using a daily x 3 schedule.
    Dosik GM; Stewart D; Valdivieso M; Burgess MA; Bodey GP
    Cancer Treat Rep; 1982 Jan; 66(1):73-6. PubMed ID: 7053269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.
    Von Hoff DD; Green SJ; Neidhart JA; Fabian C; Budd T; Boyd JF; Osborne CK
    Invest New Drugs; 1991 Feb; 9(1):87-8. PubMed ID: 2026487
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase I study of L-alanosine (NSC 15353).
    Goldsmith MA; Ohnuma T; Spigelman M; Greenspan EM; Holland JF
    Cancer; 1983 Feb; 51(3):378-80. PubMed ID: 6821823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma.
    Creagan ET; Long HJ; Ahmann DL; Green SJ
    Am J Clin Oncol; 1984 Oct; 7(5):543-4. PubMed ID: 6507375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of alanosine in advanced large bowel carcinoma.
    Rubin J; Hineman V; Moertel CG; Schutt AJ; Hahn RG
    Am J Clin Oncol; 1983 Apr; 6(2):191-3. PubMed ID: 6829493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine.
    Batova A; Cottam H; Yu J; Diccianni MB; Carrera CJ; Yu AL
    Blood; 2006 Feb; 107(3):898-903. PubMed ID: 16234352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
    Warrell RP; Arlin ZA; Kempin SJ; Young CW
    Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluation of bisantrene in acute leukemia. A Southwest Oncology Group Study.
    Mills GM; Dahlberg S; Cowan J; Neilan BA; Gumbart CH; Hussein K; Coltman CA
    Am J Clin Oncol; 1989 Dec; 12(6):507-10. PubMed ID: 2589232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro.
    Batova A; Diccianni MB; Omura-Minamisawa M; Yu J; Carrera CJ; Bridgeman LJ; Kung FH; Pullen J; Amylon MD; Yu AL
    Cancer Res; 1999 Apr; 59(7):1492-7. PubMed ID: 10197619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study with neocarzinostatin: tolerance to two hour infusion and continuous infusion.
    Ohnuma T; Nogeire C; Cuttner J; Holland JF
    Cancer; 1978 Oct; 42(4):1670-9. PubMed ID: 152143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neocarzinostatin: a phase I clinical trial with five-day intermittent and continuous infusions.
    McKelvey EM; Burgess MA; McCredie KB; Murphy WK; Bodey GP
    Cancer; 1979 Oct; 44(4):1182-8. PubMed ID: 159119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased tumor control rates in murine fibrosarcoma by combined therapy with L-alanosine and radiation.
    Hong SS; Alfieri AA; Kim SH; Kim JH
    Jpn J Cancer Res; 1989 Jun; 80(6):592-6. PubMed ID: 2503478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I study of the combination N-(phosphonacetyl)-L-aspartate (PALA, NSC-224131) and L-alanosine (NSC-153353) in patients with advanced cancer.
    Creagan ET; O'Connell MJ; Kovach JS
    Cancer; 1983 Aug; 52(4):615-8. PubMed ID: 6861099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of neocarzinostatin in patients with acute leukemia.
    Van Echo DA; Wiernik PH
    Cancer Treat Rep; 1978 Sep; 62(9):1363-5. PubMed ID: 150945
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
    Dabich L; Bull FE; Beltran G; Athens JW; Coltman CA; Weick JK; Van Slyck EJ; Amare M
    Cancer Treat Rep; 1986 Aug; 70(8):967-9. PubMed ID: 3460700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
    Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
    Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
    Tamura K
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial clinical study with pyrazofurin.
    Ohnuma T; Holland JF
    Cancer Treat Rep; 1977; 61(3):389-94. PubMed ID: 872139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rubidazone in combination with Ara-C, vincristine and prednisone (ROAP) in the treatment of adult acute leukemia. A Southwest Oncology Group Study.
    Morrison FS; Benjamin R; Amare M; Costanzi JJ; Hussein K; Ryan DH; Balcerzak S; Pendleton OJ
    Am J Clin Oncol; 1982 Dec; 5(6):645-8. PubMed ID: 7165008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.